ClinicalTrials.gg
CompletedNCT01169298Updated Nov 8, 2019

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

A Phase 1 interventional study of Lenalidomide in Adult T-cell Leukemia-Lymphoma and Peripheral T-cell Lymphoma, sponsored by Celgene. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan — none open to participants now, 2 under way, none of them phase 3. Leukemia-Lymphoma, Adult T-Cell · Japan.

Enrollment
9th of 10
13 · median 36
Started
2010
with 1 other
Phase 1
3 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Celgene

Among the 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan, this one is the 9th largest by enrollment, is one of 2 that started in 2010, is one of 3 in phase 1, and was the 5th registered.

Leukemia-Lymphoma, Adult T-Cell

31 studies on the registry are indexed under Leukemia-Lymphoma, Adult T-Cell; 5 are open to participants now.

Browse Leukemia-Lymphoma, Adult T-Cell studies →

Open to participants now

None of the 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan is open now. The open studies under Leukemia-Lymphoma, Adult T-Cell, anywhere →

Who these studies take

Of the 5 Leukemia-Lymphoma, Adult T-Cell studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Leukemia-Lymphoma, Adult T-Cell with a site in Japan as a file.
02

Study summary

To determine the maximum tolerated dose of lenalidomide in patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) who have previously received therapy for ATL and PTCL

03

Conditions studied

  • Adult T-cell Leukemia-Lymphoma
  • Peripheral T-cell Lymphoma

Keywords

  • Adult T-cell Leukemia-Lymphoma
  • Peripheral T-cell Lymphoma
  • PTCL
  • HTLV-1
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must understand and voluntarily sign the written ;
  2. Aged 20 years or older;
  3. Subject have a documented diagnosis of either:

    • Acute-, lymphoma-, or unfavorable chronic-type ATL or
    • Peripheral T-cell Lymphomaperipheral (PTCL)
  4. Subject have received ≥1 prior anti-cancer therapy, have achieved stable disease (SD) or better on their immediately prior therapy and have or progressed at the time of obtaining signed informed consent;
  5. Subject have an performance status (ECOG PS) of 0 to 2 at enrollment;

Exclusion criteria

Exclusion Criteria:

  1. Natural Killer cell lymphoma (NK-cell lymphoma);
  2. T-cell leukemia;
  3. Cutaneous T-cell lymphoma (CTCL) including;

    • Mycosis fungoides
    • Sezary syndrome
    • CD30-positive lympho-proliferative disorders
    • Cutaneous gamma/delta T-cell lymphoma
  4. Subject have a history of central nervous system (CNS) involvement or present with CNS symptoms, and are diagnosed with CNS lymphoma by cerebrospinal fluid (CSF) cytology examination, head CT scan or brain MRI during the screening;
  5. Are pregnant or lactating;
  6. Subject have uncontrolled inter-current illness including:

    • Uncontrolled diabetes mellitus
    • Chronic congestive heart failure ( Class III or IV)
    • Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug)
    • cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia
    • Other uncontrolled diseases
  7. Exhibit grade 4 neurological disorders;
  8. Subject have a history or complication of deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment;
  9. Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs;
  10. Are tested positive for HBs antigen, anti- antibody, or anti- antibody;
  11. Subjects have a history or complication for which the investigator or subinvestigator deems them inappropriate for this study, or have serious diseases or mental illness that is likely to be aggravated by participation in this study;
  12. Subjects have a history of stem cell transplantation;
  13. Subjects have received autologous stem cell transplantation within 12 weeks (84 days) of the start of study treatment;
  14. Have previously used lenalidomide;
  15. Have a history of desquamating (bullous) rash while taking thalidomide;
  16. Have received any drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication;
  17. Have received chemotherapeutic agents or immunomodulators for the treatment of ATL or PTCL within 4 weeks (28 days) of the start of study treatment;
  18. Have received radiotherapy within 4 weeks (28 days) of the start of study treatment;
  19. Have a history or complication of another malignant tumor than ATL or PTCL (excluding malignant tumors below), unless the patients have been free of the disease for 5 years or longer;

    • Cutaneous basal cell carcinoma or squamous cell carcinoma
    • Cervical carcinoma in situ
    • An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
  20. Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the enrollment;

    • : \< 1,200/µL (1.2 x 109/L)
    • count: \< 75,000/µL (75 x 109/L)
    • Serum / Serum glutamic oxaloacetic transaminase (AST/SGOT) or Alanine transaminase/Serum Glutamic Pyruvate Transaminase (ALT/SGPT): > 3 times the (ULN)
    • level: > 1.5 times of the ULN
    • : \< 60 mL/min
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)

    Drug: Lenalidomide

Interventions

  • Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)

06

What researchers measure

Primary outcomes

  1. The safety of lenalidomide evaluated based on the severity of adverse events and their causality

    The safety of lenalidomide evaluated based on the severity of adverse events and their causality

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Response

    The response of ATL patient to lenalidomide will be evaluated according to the criteria proposed by the International Consensus Meeting. The response of PTCL will be assessed by the Japan Clinical Oncology Group (JCOG) response criteria that have been established by the Lymphoma Study Group of the JCOG based on criteria of Cheson et al.in the Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    Time frame: Up to 2.5 years

  2. PK-Time to Maximum Plasma Concentration (Tmax)

    PK-Time to Maximum Plasma Concentration (Tmax)

    Time frame: Day 8 of Cycle 1

  3. PK-Apparent Total Body Clearance (CL/F)

    PK-Apparent Total Body Clearance (CL/F)

    Time frame: Day 8 of Cycle 1

  4. PK-Apparent Volume of Distribution (Vz/F)

    PK-Apparent Volume of Distribution (Vz/F)

    Time frame: Day 8 of Cycle 1

  5. PK-Terminal half-life (T1/2)

    PK-Terminal half-life (T1/2)

    Time frame: Day 8 of Cycle 1

  6. PK-Area under the Plasma concentration time curve (AUC)

    PK-Area under the Plasma concentration time curve (AUC)

    Time frame: Day 8 of Cycle 1

  7. Accumulation ratio (Cmax)

    Accumulation ratio (Cmax)

    Time frame: Day 8 of Cycle 1

  8. Accumulation ratio (AUCτ)

    Accumulation ratio (AUCτ)

    Time frame: Day 8 of Cycle 1

  9. PK-Maximum Concentration in Plasma (Cmax)

    PK-Maximum Concentration in Plasma (Cmax)

    Time frame: Day 8 of cycle 1

07

Study locations

6 sites
  • National Kyusyu Cancer Center
    Fukuoka, 811-1395, Japan
  • Imamura Bun-in Hospital
    Kagoshima, 890-0064, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
  • Nagoya Daini Red Cross Hospital
    Nagoya, 466-8650, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
08

References and documents

Publications

  • Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Midorikawa S, Ohtsu T, Tobinai K. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016 Mar;3(3):e107-18. doi: 10.1016/S2352-3026(15)00284-7. Epub 2016 Feb 12. PubMed 26947199 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2010 to primary completion in Dec 2013, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2010
First posted
Jul 26, 2010
StartActual
Jul 1, 2010
Primary completionActual
Dec 1, 2013
CompletionActual
Dec 20, 2013
Last update
Nov 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01169298
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jul 26, 2010
Start date
Jul 1, 2010
Primary completion
Dec 1, 2013
Completion
Dec 20, 2013
Last update
Nov 8, 2019

Study contacts

Hiroya Asou, MD
study director · Celgene KK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion